Somatostatin analogs have 2 roles in gastroenteropancreatic neuroendocrine tumors (GEP-NETS): treating symptoms related to the tumors and controlling tumor growth, explained Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque.
Somatostatin analogs have 2 roles: treating symptoms related to gastroenteropancreatic neuroendocrine tumors (GEP-NETS) and controlling tumor growth, explained Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque.
TranscriptHow have somatostatin analogs enhanced the treatment landscape of gastroenteropancreatic neuroendocrine tumors?
So, somatostatin analogs are extremely important. They have 2 roles. They have the role to treat symptoms related to these tumors because many of these tumors will secrete hormones, and we can control some of that with the use of somatostatin analogs. But, it’s also very important as a treatment in terms of controlling tumor growth. We know from the CLARINET and the PROMID trials that the use of somatostatin analogs as first-line treatment in the metastatic setting or in patients with locally advanced disease delays tumor growth of these tumors.
So, it’s extremely fundamental for the treatment landscape of neuroendocrine tumors, the use of somatostatin analogs.
How does sequential treatment with these therapies impact clinical outcomes?
We typically use somatostatin analogs as the first line for patients, and the general consensus in the neuroendocrine tumors field is that they are very interchangeable. So, you start with one, and then when you progress, you should change classes of treatment. However, there is some interesting new data, a retrospective analysis coming out and saying that perhaps there might be a role to switching somatostatin analogs before jumping to a completely different class of therapies.
We truly don’t know that, so for the time being, so we typically will use 1 of the 2 commercially available somatostatin analogs as the first line, and then at the time of progression, if you’re just doing it for tumor control and patients don’t have any symptoms, then you will switch to a completely different class of treatment or intervention. But, I’m very interested in this new data coming out that perhaps there might be a role of sequention with somatostatin analogs. It’s too early to tell, but we’ll see when more studies come out.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More